These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32576471)

  • 1. UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    Dyson JK; Jones DEJ
    J Hepatol; 2020 Sep; 73(3):499-501. PubMed ID: 32576471
    [No Abstract]   [Full Text] [Related]  

  • 2. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and Treatment of Primary Biliary Cholangitis].
    Kim KA
    Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Transplantation for Primary Biliary Cholangitis.
    Martin EF
    Clin Liver Dis; 2022 Nov; 26(4):765-781. PubMed ID: 36270728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Primary Biliary Cholangitis including Transplantation.
    Muzahim Y; Wakil A; Bassi M; Pyrsopoulos N
    Clin Liver Dis; 2024 Feb; 28(1):103-114. PubMed ID: 37945152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of Liver Transplantation for Primary Biliary Cholangitis.
    Aguilar MT; Carey EJ
    Clin Liver Dis; 2018 Aug; 22(3):613-624. PubMed ID: 30259857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UDCA, PBC and biochemistry: what does normal mean?
    Lindor KD
    Gut; 2000 Jan; 46(1):8. PubMed ID: 10601046
    [No Abstract]   [Full Text] [Related]  

  • 11. Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis.
    Shimoyama S; Kawata K; Ohta K; Chida T; Suzuki T; Tsuneyama K; Shimoda S; Kurono N; Leung PSC; Gershwin ME; Suda T; Kobayashi Y
    Eur J Immunol; 2021 Jun; 51(6):1519-1530. PubMed ID: 33710617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The revival of preemptive UDCA therapy in liver transplant recipients: Commentary to "UDCA decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis" by Pedersen et al., Liver Transplant, November 2020.
    Corpechot C
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101679. PubMed ID: 33727161
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatocellular Carcinoma in Primary Biliary Cholangitis.
    Sy AM; Ferreira RD; John BV
    Clin Liver Dis; 2022 Nov; 26(4):691-704. PubMed ID: 36270724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding the cure for primary biliary cholangitis - Still waiting.
    Tanaka A; Gershwin ME
    Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
    Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
    Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
    [No Abstract]   [Full Text] [Related]  

  • 18. Seladelpar in patients with primary biliary cholangitis: Need for a closer look!
    Mishra AK; Singh SP
    J Hepatol; 2022 Nov; 77(5):1451. PubMed ID: 35594993
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of primary biliary cirrhosis with ursodeoxycholic acid].
    Nikolovska D; Vasilev P; Mikhova A
    Vutr Boles; 2000; 32(1):25-7. PubMed ID: 11195193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
    Kotb MA
    Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.